Navigation Links
Kenrico Announces Records of Patents for 2012 and Financial Targets for 2013
Date:1/22/2013

Shimada, Japan (PRWEB) January 22, 2013

Shimada, Japan, January 18, 2013, Kenrico today announced that it received a record of patents in 2012 for inventions that will enable fundamental advancement across key medical devices and nutraceutical treatments including toxins absorbing patch, sporopollenin based toxins extraction (TRMX-3 ®), nattokinase based toxins extraction (LEXIRIN ®), as well as industry solutions for healthcare. These patented inventions will advance a major shift in health treatment.

“We are proud of this new benchmark in biological and scientific creativity, which grows out of Kenrico’s century-long commitment to research and development,” said Nurman Salim, chairman and CEO, Kenrico. “Our patent record and leadership are a testament to our devotion that matters for our distributor, for our company and for the world.”

The Top Four list of 2012 patents includes:

  •     TOXINS ABSORBING PATCH, a SAP SHEET ® or commonly known as foot pads or detoxification pads, is a medical treatment based on Japanese toxins cleansing technology (US Patent 8,317,762 – International Patent 12/267,731) invented by Suzuki, M.D (Pharmacologist, Kenrico) and Nurman Salim (Biophysical Scientist, Kenrico) and manufactured by Kenrico in Japan. It provides a complete cure to a wide range of medical conditions with effectiveness documented by numerous independent clinical studies.
  •     TRMX-3 ® (Supreme Gold Edition), the company's sporopollenin based toxins extractor (US Patent 7,182,965 – Japanese Patent 4485940 – European Patent 03720506.09), was approved by Health Canada in Canada and in Europe by European Medical Device Agency. Separately, the company entered into strategic agreements with pharmaceutical companies to market nattokinase based Lexirin globally to physician for prevention of cell death. Apoptotic cell death plays a significant role in the tissue damage that occurs in association with aging and various abnormal conditions, for example, ischemia and various gastrointestinal disorders.
  •     LEXIRIN ® (US Patent 6,793,945 – 6,413,556), is a medical breakthrough in the treatment of gastrointestinal disorders, deleterious dermatological conditions, immunosuppression or immunodeficiency, reperfusion damage resulting from ischemia, cardiovascular disorders, transplantation, wound healing, tissue rejection and Alzheimer's disease, and the treatment of adverse reactions from medications. LEXIRIN also can significantly decrease conditions and diseases related to aging and blocked blood circulation. LEXIRIN has passed US FDA's Phase I human clinical trials at Alta Bates Medical Center in Berkeley.
  •     ION SHOWER HEAD EX ®, ION WATER PURIFIER ®, FOREVER ALKALINE WATER STICK PURIFIER ®. A technological advancement in water treatment technology that blends natural quartz, citrine crystals and natural minerals from Japanese hot springs for health and stress treatment.

Financial targets
Kenrico continues to expect full year 2013 revenue to double from a base of $149 million in 2012.

In addition, the company updated its anticipated consolidated tax rate to range of 10 percent.

About Kenrico
Kenrico is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1985, Kenrico currently discovers, develops, manufactures and markets prescription and alternative medicines to address unmet medical needs. The Company operates two manufacturing facilities in Shimada and Kanaya, Japan. For more information, visit http://www.kenrico.com. For a list of commercial broadcasting, visit http://www.kenrico.com/tvcommercial.html.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10337739.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an ... treatment of Alzheimer’s disease, announced today it has been selected to present at the ... Breakers in Palm Beach, Florida. The purpose of the Forum is to help ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
Breaking Biology News(10 mins):